TY  - JOUR
AU  - Noli, B.
AU  - Muqaku, B.
AU  - Gouda, M.
AU  - Manai, A. L.
AU  - Nagl, M.
AU  - Anderl-Straub, S.
AU  - Werner, L.
AU  - Otto, M.
AU  - Teunissen, C. E.
AU  - Oeckl, P.
AU  - Cocco, C.
TI  - VGF AQEE- and GGEE-peptides differentiate between dementia types.
JO  - Journal of neurology
VL  - 272
IS  - 11
SN  - 0367-004X
CY  - [Darmstadt]
PB  - Steinkopff
M1  - DZNE-2025-01226
SP  - 745
PY  - 2025
AB  - Alzheimer's disease (AD) and dementia with Lewy bodies (DLB) are neurodegenerative disorders with overlapping clinical features, making differential diagnosis challenging. The AQEE and GGEE peptides, derived from the proVGF neuroprotein, have emerged as potential cerebrospinal fluid (CSF) biomarkers for dementia. Indeed, we previously observed a reduction in AQEE-10 levels using selected reaction monitoring (SRM) and GGEE levels using enzyme-linked immunosorbent assay (ELISA) in a cohort of DLB patients compared to both controls and AD patients. To better investigate the diagnostic utility of these peptides, we analyzed CSF samples from both the original cohort and a newly recruited cohort. The new cohort (cohort 1) included patients, from Ulm University Hospital, with Parkinson's disease dementia (PDD) and DLB (combined as PDD/DLB; n = 18), and AD (n = 19). The previously analyzed cohort (cohort 2), from the Amsterdam University Medical Center, included DLB (n = 44), AD (n = 20), and cognitively healthy controls (n = 22). AQEE-10 levels were quantified by multiple reaction monitoring (MRM) in cohort 1 and by ELISA in both cohorts. GGEE levels were measured by ELISA in cohort 1 to corroborate and extend previous findings. MRM-based analysis revealed a significant reduction of AQEE-10 levels in DLB compared to both controls and AD (p < 0.05; ROC-AUC: 78
KW  - Humans
KW  - Male
KW  - Female
KW  - Aged
KW  - Lewy Body Disease: cerebrospinal fluid
KW  - Lewy Body Disease: diagnosis
KW  - Biomarkers: cerebrospinal fluid
KW  - Alzheimer Disease: cerebrospinal fluid
KW  - Alzheimer Disease: diagnosis
KW  - Aged, 80 and over
KW  - Cohort Studies
KW  - Parkinson Disease: cerebrospinal fluid
KW  - Parkinson Disease: diagnosis
KW  - Enzyme-Linked Immunosorbent Assay
KW  - Middle Aged
KW  - Dementia: cerebrospinal fluid
KW  - Dementia: diagnosis
KW  - Diagnosis, Differential
KW  - ROC Curve
KW  - Nerve Growth Factors
KW  - Alzheimer´s disease (Other)
KW  - Biomarker (Other)
KW  - Cerebrospinal fluid (Other)
KW  - Lewy Body dementia (Other)
KW  - Neuroprotein (Other)
KW  - VGF (Other)
KW  - Biomarkers (NLM Chemicals)
KW  - VGF protein, human (NLM Chemicals)
KW  - Nerve Growth Factors (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:41186756
DO  - DOI:10.1007/s00415-025-13441-1
UR  - https://pub.dzne.de/record/281853
ER  -